JP2020515577A5 - - Google Patents

Download PDF

Info

Publication number
JP2020515577A5
JP2020515577A5 JP2019553112A JP2019553112A JP2020515577A5 JP 2020515577 A5 JP2020515577 A5 JP 2020515577A5 JP 2019553112 A JP2019553112 A JP 2019553112A JP 2019553112 A JP2019553112 A JP 2019553112A JP 2020515577 A5 JP2020515577 A5 JP 2020515577A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
seq
antibody
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019553112A
Other languages
English (en)
Japanese (ja)
Other versions
JP7237848B2 (ja
JP2020515577A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/024316 external-priority patent/WO2018183182A1/en
Publication of JP2020515577A publication Critical patent/JP2020515577A/ja
Publication of JP2020515577A5 publication Critical patent/JP2020515577A5/ja
Priority to JP2022211248A priority Critical patent/JP2023052145A/ja
Application granted granted Critical
Publication of JP7237848B2 publication Critical patent/JP7237848B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019553112A 2017-03-27 2018-03-26 免疫原性の低下のための方法及び組成物 Active JP7237848B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022211248A JP2023052145A (ja) 2017-03-27 2022-12-28 免疫原性の低下のための方法及び組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762477257P 2017-03-27 2017-03-27
US62/477,257 2017-03-27
PCT/US2018/024316 WO2018183182A1 (en) 2017-03-27 2018-03-26 Methods and compositions for reduction of immunogenicity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022211248A Division JP2023052145A (ja) 2017-03-27 2022-12-28 免疫原性の低下のための方法及び組成物

Publications (3)

Publication Number Publication Date
JP2020515577A JP2020515577A (ja) 2020-05-28
JP2020515577A5 true JP2020515577A5 (https=) 2021-05-13
JP7237848B2 JP7237848B2 (ja) 2023-03-13

Family

ID=62002401

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019553112A Active JP7237848B2 (ja) 2017-03-27 2018-03-26 免疫原性の低下のための方法及び組成物
JP2022211248A Pending JP2023052145A (ja) 2017-03-27 2022-12-28 免疫原性の低下のための方法及び組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022211248A Pending JP2023052145A (ja) 2017-03-27 2022-12-28 免疫原性の低下のための方法及び組成物

Country Status (15)

Country Link
US (2) US20200330590A1 (https=)
EP (1) EP3601351A1 (https=)
JP (2) JP7237848B2 (https=)
KR (1) KR20190133198A (https=)
CN (1) CN110612309A (https=)
AU (1) AU2018244276A1 (https=)
BR (1) BR112019020185A2 (https=)
CA (1) CA3057841A1 (https=)
CL (1) CL2019002716A1 (https=)
CO (1) CO2019011640A2 (https=)
EA (1) EA201992278A1 (https=)
IL (1) IL269590A (https=)
MX (1) MX2019011624A (https=)
SG (1) SG11201908678XA (https=)
WO (1) WO2018183182A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
MX2017010072A (es) * 2015-02-05 2017-11-09 Molecular Templates Inc Moleculas multivalentes que se enlazan a cd20, las cuales comprenden regiones efectoras de la subunidad a de la toxina shiga, y composiciones enriquecidas de las mismas.
AU2019257343A1 (en) 2018-04-17 2020-09-10 Molecular Templates, Inc. HER2-targeting molecules comprising de-immunized, Shiga toxin A Subunit scaffolds
TW202045550A (zh) 2019-04-05 2020-12-16 美商西建公司 腫瘤選擇性結合cd47之抗體之工程
CN114206912B (zh) 2019-06-07 2025-02-11 Alx肿瘤生物技术公司 用于在血清学测定中减少结合cd47的药物的干扰的方法和试剂
KR20220091576A (ko) * 2019-10-31 2022-06-30 포티 세븐, 인코포레이티드 혈액암의 항-cd47 및 항-cd20 기반 치료
CA3163939A1 (en) * 2020-01-09 2021-07-15 Innovent Biologics (Suzhou) Co., Ltd. Application of combination of anti-cd47 antibody and anti-cd20 antibody in preparation of drugs for preventing or treating tumors
JP2023545983A (ja) 2020-10-07 2023-11-01 セルジーン コーポレイション リンパ系悪性腫瘍状態の二重特異性抗体治療
WO2022120286A1 (en) 2020-12-06 2022-06-09 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5869620A (en) 1986-09-02 1999-02-09 Enzon, Inc. Multivalent antigen-binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
AU701578B2 (en) 1992-08-21 1999-02-04 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
WO1994025591A1 (en) 1993-04-29 1994-11-10 Unilever N.V. PRODUCTION OF ANTIBODIES OR (FUNCTIONALIZED) FRAGMENTS THEREOF DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF $i(CAMELIDAE)
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
US5989830A (en) 1995-10-16 1999-11-23 Unilever Patent Holdings Bv Bifunctional or bivalent antibody fragment analogue
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
HUP0000116A3 (en) 1996-10-01 2000-08-28 Stanford Res Inst Int Taste-masked microcapsule compositions and methods of manufacture
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US7951917B1 (en) 1997-05-02 2011-05-31 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
DE60042789D1 (de) 1999-11-29 2009-10-01 Bac Ip B V Immobilisierte antigenbindende moleküle aus einer domäne
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
WO2005035575A2 (en) 2003-08-22 2005-04-21 Medimmune, Inc. Humanization of antibodies
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
EP2111869A1 (en) * 2008-04-23 2009-10-28 Stichting Sanquin Bloedvoorziening Compositions and methods to enhance the immune system
JP5816170B2 (ja) 2009-06-26 2015-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッドRegeneron Pharmaceuticals, Inc. 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体
US20140140989A1 (en) 2012-02-06 2014-05-22 Inhibrx Llc Non-Platelet Depleting and Non-Red Blood Cell Depleting CD47 Antibodies and Methods of Use Thereof
PL2859017T3 (pl) 2012-06-08 2019-07-31 Sutro Biopharma, Inc. Przeciwciała zawierające swoiste dla miejsca, niewystępujące naturalnie reszty aminokwasowe, sposoby ich wytwarzania i sposoby ich zastosowania
HRP20220455T1 (hr) 2012-08-31 2022-05-27 Sutro Biopharma, Inc. Modificirane aminokiseline koje sadrže azid grupu
MX2015007446A (es) * 2012-12-12 2015-12-07 Vasculox Inc Anticuerpos terapeuticos para cd47.
CN105101997B (zh) * 2013-02-06 2018-11-09 印希彼有限合伙公司 不减少血小板和不减少血红细胞的cd47抗体及其使用方法
US20170002060A1 (en) * 2014-01-08 2017-01-05 Moderna Therapeutics, Inc. Polynucleotides for the in vivo production of antibodies
WO2016109415A1 (en) * 2014-12-30 2016-07-07 Celgene Corporation Anti-cd47 antibodies and uses thereof
NZ741324A (en) * 2015-09-21 2021-09-24 Erasmus Univ Medical Center Anti-cd47 antibodies and methods of use

Similar Documents

Publication Publication Date Title
JP2020515577A5 (https=)
JP2021524256A5 (https=)
JP2021527431A5 (https=)
JP2008540447A5 (https=)
JP2020527332A5 (https=)
JP2020520370A5 (https=)
JP2008530142A5 (https=)
JP2021531764A5 (https=)
IL313952A (en) Combination of anti-PD-1 antibodies and bispecific anti-CD20 / anti-CD3 antibodies for cancer treatment
JP2018534933A5 (https=)
JPWO2019246514A5 (https=)
JP2017529838A5 (https=)
JP2021510736A5 (https=)
JP2015534579A5 (https=)
JP2014533279A5 (https=)
JP2020503260A5 (https=)
JP2019515008A5 (https=)
JP2017514795A5 (https=)
JP2019529373A5 (ja) 抗Tim−3抗体
JP2020501531A5 (https=)
JP2017501157A5 (https=)
JP2017534256A5 (https=)
JP2011507932A5 (https=)
JP2016503067A5 (https=)
CA3232806A1 (en) B7-h4 antibody-drug conjugates for the treatment of cancer